Serum prostate-specific antigen levels in older men with or at risk of HIV infection

HIV Medicine

Volumn 7, Issue 7, 2006, Pages 471-476

  Vianna, L E ^a   Lo, Y ^a   Klein, Robert S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ageing; Men's health; Prostate; Prostate specific antigen

Indexed keywords

ANDROGEN; CD4 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; ANAMNESIS; ANTIGEN DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CHI SQUARE TEST; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; ETHNIC DIFFERENCE; FAMILY HISTORY; FISHER EXACT TEST; HEALTH BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; KRUSKAL WALLIS TEST; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE CANCER; RANK SUM TEST; RISK ASSESSMENT; SEROLOGY; SEXUAL BEHAVIOR; STUDENT T TEST; T LYMPHOCYTE SUBPOPULATION; UROLOGIC EXAMINATION;

AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 33747663741     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00410.x     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep 1992; 41 (RR-17): 1-19.
2. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32: 527-533.
3. Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E for the AIDS Cancer Match Study Group. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36: 861-868.
4. Blattner WA. Human retroviruses: Their role in cancer. Proc Assoc Am Physicians 1999; 111: 563-572.
5. Bellan C, De Falco G, Lazzi S, Leoncini L. Pathologic aspects of AIDS malignancies. Oncogene 2003; 22: 6639-6645.
6. Leibovitz A, Baumoehl Y, Segal R. Increased incidence of pathological and clinical prostate cancer with age: Age related alterations of local immune surveillance. J Urol 2004; 172: 435-437.
7. Tirelli U, Bernardi D, Spina M, Vaccher E. AIDS-related tumors: integrating antiviral and anticancer therapy. Crit Rev Oncol Hematol 2002; 41: 299-315.
8. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001; 37: 1316-1319.
9. Merrill RM, Weed DL. Measuring the public health burden of cancer in the United States through lifetime and age-conditional risk estimates. Ann Epidemiol 2001; 11: 547-553.
10. Yancik R, Ries LAG. Cancer in older persons: An international issue in an aging world. Semin Oncol 2004; 31: 128-136.
11. Denduluri N, Ershler WB. Aging biology and cancer. Semin Oncol 2004; 31: 137-148.
12. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-1830.
13. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15: 629-633.
14. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468-476.
15. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
16. Piketty C, Darragh TM, Heard I et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis 2004; 31: 96-99.
17. Bedimo R, Chen RY, Accortt NA et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39: 1380-1384.
18. Centers for Disease Control and Prevention. Prostate Cancer: The Public Health Perspective (Fact Sheet 2003). http://www.cdc.gov/cancer/prostate/ prostate.htm 2005.
19. Crum NF, Hale B, Utz G, Wallace M. Increased risk of prostate cancer in HIV infection? AIDS 2002; 16: 1703-1704.
20. Schwartz JD, Prince D. Prostate cancer in HIV infection. AIDS 1996; 10: 797-798.
21. Serraino D, Boschini A, Carrieri P et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14: 553-559.
22. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16: 1155-1161.
23. Purvis Cooper C, Merritt TL, Ross LE, John LV, Jorgensen CM. To screen or not to screen, when clinical guidelines disagree: Primary care physicians' use of the PSA test. Prevent Med 2004; 38: 182-191.
24. Wilson SS, Crawford ED. Screening for prostate cancer: Current recommendations. Urol Clin North Am 2004; 31: 219-226.
25. Schmid HP, Riesen W, Prikler L. Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004; 50: 71-78.
26. Cooner WH, Mosley BR, Rutherford CL et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146-1152.
27. Brawley OW, Knopf K, Merrill R. The epidemiology of prostate cancer. I. Descriptive epidemiology. Semin Urol Oncol 1998; 16: 187-192.
28. Oesterling JE. Age-specific reference ranges for serum PSA. N Engl J Med 1996; 335: 345-346.
29. Thompson IM, Pauler DK, Goodman P et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
30. Shirai T, Asamoto M, Takahashi S, Imaida K. Diet and prostate cancer. Toxicology 2002; 181-182: 89-94.
31. Crawford ED. Epidemiology of prostate cancer. Urology 2003; 62 (Suppl. 1): 3-12.
32. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation (letter). Lancet 2000; 355: 1886-1887.
33. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-86. Int J Cancer 1995; 60: 183-189.
34. Pecqueux JC, Schwarz A, Dieckmann KP, Offermann G. Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int 1990; 45: 290-292.
35. Fraumeni JFJ, Hoover R. Immunosurveillance and cancer: Epidemiologic observations. Natl Cancer Inst Monogr 1977; 47: 121-126.
36. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-1181.
37. Bayne A, Barry JM, Garzatto M. Radical retropubic prostatectomy after orthoptic liver transplantation. Urology 2005; 65: 175.
38. Konety BR, Tewari A, Howard RJ et al. Prostate cancer in the post-transplant population. Urology 1998; 52: 428-432.
39. Ciancio G, Antun RA, Norberg DG, Mitrani AA, de Marchena E, Soloway MS. Prostate cancer after heart transplantation. J Urol 1995; 153: 158-160.
40. Crum NF, Spencer CR, Amling CL. Prostate cancer among men with human immunodeficiency virus infection. Cancer 2004; 101: 294-299.